BAM
PCVX icon

Bellevue Asset Management’s Vaxcyte PCVX Stock Holding History

Bellevue Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23
Closed -$1.88K – 497
2024
Q4 		$1.88K Hold
23
– – ﹤0.01% 445
2024
Q3 		$2.63K Hold
23
– – ﹤0.01% 383
2024
Q2 		$1.74K Hold
23
– – ﹤0.01% 426
2024
Q1 		$1.57K Hold
23
– – ﹤0.01% 432
2023
Q4 		$1.44K Buy
+23
New +$1.2K ﹤0.01% 430

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bellevue Asset Management's PCVX Position: Q1 2025 in Review

Bellevue Asset Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 23 shares — an estimated $1.88K sold.

Bellevue Asset Management first reported a position in PCVX in Q4 2023 and held it in 5 quarters. The position peaked at $2.63K in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Bellevue Asset Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Bellevue Asset Management sold 23 Vaxcyte shares in Q1 2025, an estimated $1.88K.
  • Bellevue Asset Management first reported a position in Vaxcyte in Q4 2023 and held it in 5 quarters.
  • Bellevue Asset Management's Vaxcyte position peaked at $2.63K in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Bellevue Asset Management's 13F filing for Q1 2025, filed 28 Apr 2025.